In this study, the established acquisition protocol for relaxation-compensated APT and rNOE CEST-MRI at 7 T has been successfully transferred to a clinically relevant magnetic field strength of 3 T. This opens up the door to clinical trials with a large number of participants, thus enabling a comprehensive assessment of the clinical relevance of relaxation-compensation in CEST-MRI. The presented CEST sequence is currently part of the clinical routine acquisition protocol for brain tumor patients at our institute.
This abstract and the presentation materials are available to members only; a login is required.